Zielen, S; Kuna, P; Aberer, W; Lassmann, S; Wade, A; Kluehr, K; Raab, J; Lee, D; Ballard, R; Jones, C; Gunawardena, K; Skinner, MA; Higenbottam, T.
Design of a phase II allergen immunotherapy study to determine the optimally effective and safe dose of subcutaneously administered tyrosine adsorbed modified grass allergen plus MPL
ALLERGY. 2018; 73: 487-488.-Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI); MAY 26-30, 2018; Munich, GERMANY.
[Oral Communication]
Web of Science